Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00226772 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction

A Phase 3 study, sponsored by Omeros Corporation.

Completed
Registry status
Phase 3
Development phase
326
Enrollment target

NCT00226772: Completed Phase 3 study, sponsored by Omeros Corporation.

NCT00226772 is a Phase 3 study that has completed, run by Omeros Corporation. The registered enrollment target is 326 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00226772, a Phase 3 study, has completed, sponsored by Omeros Corporation.

COMPLETED
Registry status
Phase 3
Development phase
326 participants
Enrollment target

Study Summary

The anterior cruciate ligament (ACL) is an important stabilizer of the knee. Orthopedic surgeons replace the torn ligament during ACL reconstruction surgery. Surgical trauma initiates an acute inflammatory response, including swelling and pain, that leads to restricted joint motion and loss of function. OMS103HP was designed to deliver targeted therapeutic agents directly to the surgical site during the arthroscopic procedure to inhibit inflammation and pain before they can begin. The purpose of this study is to assess the effectiveness and safety of OMS103HP in improving knee function following ACL reconstruction using a hamstring autograft. Secondary benefits being evaluated include reduced postoperative pain, improvement in knee range of motion, and earlier return to work.

Interventions

  • DRUG Vehicle
  • DRUG OMS103HP

Trial Details

FieldValue
Enrollment Target 326 participants
Start Date 2005-06
Est. Completion 2011-03
Phase Phase 3
Omeros Corporation

19 total trials

What the finished NCT00226772 record still lists

NCT00226772 is an interventional study that assigns participants to a tested intervention. The registered 326 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower).

The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.

NCT00226772 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00226772 about?

NCT00226772 is a clinical study titled "Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction". The anterior cruciate ligament (ACL) is an important stabilizer of the knee. Orthopedic surgeons replace the torn ligament during ACL reconstruction surgery. Surgical trauma initiates an acute inflammatory response, including swelling and pain, that leads to restricted joint motion and loss of funct...

What is the current status of trial NCT00226772?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 326 participants. The study started on 2005-06. Estimated completion is 2011-03.

What interventions are being tested in trial NCT00226772?

The interventions under investigation include: Vehicle (DRUG), OMS103HP (DRUG).

Who is sponsoring clinical trial NCT00226772?

This trial is sponsored by Omeros Corporation, which has 19 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00226772's enrollment target sits among peer trials

326 1075th of 2000 higher than 925 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06410144 · 326 participants · NA

    Chronic Kidney Disease-Education (CKD-EDU)

  • NCT06586619 · 326 participants · NA

    A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV

  • NCT07040566 · 326 participants · Phase 2

    A Trial of Varenicline for E-cigarette Cessation

  • NCT07165860 · 326 participants · NA

    Clinical Trial to Reduce Perinatal Intimate Partner Violence

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00226772, the US trial registry maintained by the National Library of Medicine. NCT00226772 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.